PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people worldwide to live healthier at every stage of life," said Andrew Enrietti, Chief People O ...

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences.Details of the presentations can be found below:UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m. PT / 11:45 a.m. ET Location: Terranea Resort in Rancho Palos Verdes, California Format: Fireside chat with Viatris executivesJeffries London Healthcare Conference  Date: Thursday, November 21, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

文章核心观点 - 美国制药公司Lexicon Pharmaceuticals与全球医疗公司Viatris达成独家许可协议,Viatris获得Lexicon研发的心血管药物sotagliflozin在美国和欧洲以外的全球市场的商业化权利 [1][2] - Lexicon将保留sotagliflozin在美国和欧洲的独家商业化权利,双方将通过此次合作扩大该药物的全球覆盖范围,使更多患者受益 [2] - 根据协议,Viatris将支付Lexicon2500万美元的前期付款,并有可能获得监管和销售里程碑付款以及从低个位数到中个位数的销售提成 [2] 公司概况 - Lexicon是一家生物制药公司,致力于研发能够改变患者生活的创新药物 [3] - Lexicon通过"Genome5000"计划,发现了100多个具有重大治疗潜力的蛋白质靶点,并正在针对这些靶点开发创新药物 [3] - Lexicon正在美国上市销售其首个商业化产品INPEFA(sotagliflozin),并拥有一个包括神经病理性疼痛、糖尿病和代谢等领域在内的丰富管线 [3] 药物信息 - Sotagliflozin是Lexicon利用基因科学发现的一种口服抑制剂,能抑制两种负责葡萄糖调节的蛋白质SGLT2和SGLT1 [5] - Sotagliflozin已在涉及心力衰竭、糖尿病和慢性肾脏疾病的约20,000名患者的临床研究中进行了评估 [6] - INPEFA(sotagliflozin)获批适应症为减少心血管死亡、心力衰竭住院和紧急心力衰竭就诊的风险,适用于心力衰竭或2型糖尿病、慢性肾脏疾病且有其他心血管危险因素的成人患者 [7] 合作背景 - Viatris是一家全球性医疗公司,在普通药和专利药之间架起桥梁,为全球患者提供更全面的医疗服务 [4] - Viatris拥有强大的心血管代谢疾病领域专业知识、全球商业能力和在新市场成功推出药物的良好记录 [2] - 此次合作有助于Viatris进一步拓展创新产品组合,推动未来收入的加速和持久增长 [2]

核心观点 - Viatris公司与Lexicon公司达成独家许可协议获得sotagliflozin在美国和欧洲以外所有市场的权利以扩充心血管疾病创新产品组合[1] 关于协议 - Viatris与Lexicon达成sotagliflozin的独家许可协议涉及美国和欧洲以外市场[1] - 协议条款包括Viatris向Lexicon支付2500万美元预付款以及额外潜在或有款项包括监管里程碑销售里程碑和分层版税等Viatris负责许可区域的监管和商业化活动Lexicon负责供应[5] 关于公司 - Viatris是全球医疗保健公司旨在弥合仿制药和品牌药之间的鸿沟为全球约10亿患者提供高质量药物[7] - Lexicon是生物制药公司通过Genome5000™计划识别有治疗潜力的蛋白靶点开发创新药物有多种药物处于研发阶段[9] 关于药物 - Sotagliflozin于2023年5月被美国FDA批准用于降低特定成人的心血管死亡等风险已在约20000名患者中进行研究[2][6]

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO, Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® ...

PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined bel ...

PITTSBURGH, Sept. 17, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") and that UAS has increased the maximum aggregate principal amount for the Maximum Tender Offer from up to a maximum aggregate principal amount of $450,000,000 to up to a maximum aggregate principal amount of $575,003,000 (such increased aggregat ...

文章核心观点 - Viatris Inc.将于2024年11月7日发布第三季度财报 [1] - Viatris Inc.是一家全球性医疗保健公司,致力于在通用药品和品牌药品之间架起桥梁,更全面地满足全球医疗需求 [2] - Viatris Inc.拥有广泛且多样化的药品组合,并建立了独特的全球供应链,能够在需要时及时为全世界的人们提供高质量的药品 [2] 公司概况 - Viatris Inc.总部位于美国,在匹兹堡、上海和印度海得拉巴设有全球中心 [2] - Viatris Inc.每年为全球约10亿患者提供药品,涵盖从出生到临终的各个生命阶段,从急性疾病到慢性疾病 [2] - Viatris Inc.致力于通过提供可负担的优质药品,让更多人享有健康生活 [2]

PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No. 92556VAB2/ISIN US92556VAB27) and any and a ...